Question

Is stem cell therapy for Peripheral Neuropathy worth it?

Neuropathy cell therapy offers meaningful value for patients with moderate-to-severe diabetic or painful neuropathy refractory to conventional pharmacotherapy (gabapentin, pregabalin) and lifestyle modification. Cost (€4,500–7,000 per infusion) is reasonable compared to lifelong neuropathic medication (€100–300/month) and disability costs. Response probability (~50–60%) justifies consideration for motivated patients with significant pain or functional impairment. Limitations: durability is uncertain, requiring possible re-treatment; complete sensory restoration is rare; and advanced, longstanding neuropathy with severe axonal loss may respond poorly. Best-fit candidates are age 40–70 with diabetes or known neuropathy aetiology, moderate-to-severe symptoms, failed or intolerant to conventional drugs, and realistic expectations of partial, gradual pain reduction without complete functional restoration.

How stem cells are studied for Peripheral Neuropathy

Peripheral neuropathy encompasses diverse conditions—diabetic, idiopathic, chemotherapy-induced, ischaemic—characterised by progressive nerve fibre loss, demyelination, and sensorimotor dysfunction. Stem cell therapies exploit multiple pathways: placental mesenchymal stem cells (MSCs) secrete neurotrophic factors (NGF, GDNF, VEGF) that promote nerve regeneration and angiogenesis; neurogenic cells differentiate into functional neurons to replace damaged fibres; exosomes deliver growth factor cargo directly into affected peripheral tissues. The rationale combines neuroprotection (halting further degeneration), neuroregenerative repair (sprouting of surviving axons), and vascular restoration (improving ischaemic neuropathy). Forty-six registered trials investigate efficacy across neuropathy subtypes; eight actively recruit, indicating expanding clinical capacity and commercial interest.

Am I a candidate? → · Peripheral Neuropathy: full overview → · Peripheral Neuropathy cost → · Cost →

Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.

Terapia celular de nivel europeo, sin precios europeos.

Medicina regenerativa certificada GMP en el corazón de la UE — desde 3.000–8.000 €, una fracción de los precios de EE. UU. o Alemania. Protocolos personalizados para pacientes de más de 50 países.

Evaluación médica gratuita